You are cordially invited to the

10th International Symposium on Translational Research in Oncology

Meeting Chairs: Prof John Crown (Dublin)
Prof Robert Kerbel (Toronto)

Thursday, Friday & Saturday

September 28th, 29th & 30th

Herbert Park Hotel, Ballsbridge, Dublin 4

35 Speakers include: Dr Joyce O’Shaughnessy (Texas), Dr Steve Shak (Genomic Health), Dr. Mario Sznol (Yale), Dr Maurizio Scaltriti (MSKCC), Prof Lajos Pusztai (Yale), Dr Cameron Turtle(Seattle), Dr Alessio Amatu (Milan) Dr Yihai Cao (Karolinska), Prof Noel Lowndes (NUIGalway) Prof Igor Roninson (USC), Prof Michael Barrett(Mayo Clinic)

Attendance is free but registration is required.

Register: karen.culhane@ccrt.ie
Website: http://www.ccrt.ie
CPD accreditation pending
Thursday, 28th September
Mezzanine Suite, Herbert Park Hotel, Ballsbridge, Dublin 4

Registration from 11:30

12:00 – 12:15 Welcome and Introduction – Prof. John Crown, St. Vincent’s University Hospital, Dublin

**HER-2**

12:15 – 12:45 Title: TBC
Prof. Giuseppe Gullo, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Ireland

12:45 – 1:15 Targeting somatic HER2 mutations with neratinib, a pan-HER tyrosine kinase inhibitor: translational and clinical insights.
Dr. Maurizio Scaltriti, Scientist, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York

1:15 – 1:45 Her2 Targeted Therapy for Colorectal Cancer
Dr. Alessio Amatu Consultant Medical Oncologist, Niguarda Cancer Center, Milan

1:45 – 2:30 Lunch, Herbert Suite

2:30 – 3:00 Molecular studies of HER2 treated patients
Prof. Lajos Pusztai, Director, Breast Cancer Translational Research, Yale Cancer Center Genetics, Genomics and Epigenetics Program

**TARGETED THERAPIES**

3:00 – 3:30 Vitamin D: Can it be used to treat cancer?
Prof. Joe Duffy, St. Vincent’s University Hospital, Clinical Research Centre

3:30 – 4:00 Targeting IGF signaling with Xentuzumab: an update
Dr. Thomas Bogenrieder, Department of Urology, University Hospital Grosshadern, Munich

4:00 – 4:30 CDK7: A Promising Drug Target in Breast and Other Cancers
Prof. William Gallagher, Professor of Cancer Biology, UCD School of Biomolecular and Biomedical Science, University College Dublin

4:30 – 5:00 Non-immunological molecular therapies of malignant melanoma.
Dr. Mario Sznol, Professor of Medicine, Yale Cancer Centre

5:00 – 5:30 Eribulin Mechanisms of Action: Beyond Antimitotic Effects to Complex Changes in Tumor Biology
Dr. Bruce Littlefield, Distinguished Scientist and Head, Translational Medicine, Global Oncology, Eisai Inc.

Meeting ends
Friday, 29th September
Mezzanine Suite, Herbert Park Hotel, Ballsbridge, Dublin 4

Registration from 8:30

9:00 – 9:15 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

IMMUNOTHERAPY I

Chair: Dr. Mario Sznol

9:15 – 9:45 CD19 CAR-T cell immunotherapy for B cell malignancies
Dr. Cameron Turtle, Fred Hutchinson Cancer Research Center, Seattle

9:45 – 10:15 Targeting DLL3 in SCLC: Clinical Trial Strategies for Rovalpituzumab Tesirine
Dr. Laura Saunders, Associate Director of Molecular Biology, AbbVie, San Francisco

10:15 – 10:45 Ladiratuzumab Vedotin: Discovery and development of a novel antibody drug conjugate for metastatic Triple Negative Breast Cancer
Django Sussman, PhD, Director, Protein Science, Seattle Genetics

10:45 – 11:00 Coffee break

IMMUNOTHERAPY II

Chair: Prof John Crown

11:00-11:30 Immune therapy beyond PD-1/PD-L1 blockade: is there a rational way forward?
Dr. Mario Sznol, Professor of Medicine, Yale Cancer Centre

11:30-12:00 Antagonists of A2A adenosine receptors: The disease control and examples of dramatic rejections of refractory to all other therapies tumors bodes well for adoptive immunotherapies of cancer patients as the most likely and frequent beneficiaries.
Prof. Michail Sitkovsky, Professor of Immunophysiology and Pharmaceutical Biotechnology, Northeastern University, Boston

12:00-12:30 Atezolizumab and Cancer Immunotherapy for Breast Cancer
Dr. Saeed Rafii, Medical Director Atezolizumab Breast and Gynaecologic Cancer Programme, Global Development Team, Roche/Genentech

12:30-1:30 Lunch, Herbert Suite

1:30-2:00 Checkpoint blockade and IDO inhibitors
Dr. Olivier Peeters, Regional Director Medical Affairs, Melanoma, MSD
**PERSONALIZED CANCER MEDICINE**

**Chair: Prof Robert Leonard**

2:00-2:30  
**Exosomes and Ectosomes in breast and other cancers**  
Prof. Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Science, Trinity College, Dublin

2:30-3:00  
**Personalising cancer care: the emerging role of comprehensive genomic profiling**  
Dr. Damian Page, Group International Scientific Director, Personalized Healthcare, Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel.

3:00-3:30  
**Title: TBC**  
Dr. Steve Shak, Chief Scientific Officer, Genomic Health

3:30-3:45  
**Coffee break, Herbert Suite**

3:45-4:15  
**Omic-driven clinical thinking for oncology**  
Dr. Giannoula Lakka Klement, Director Personalized Cancer Care Program, Tufts University School of Medicine, McMaster University, Boston

4.15-4:45  
**Genomic drivers and clinical outcomes**  
Prof. Michael Barrett, Translational Genomics Research Institute, Mayo Clinic Cancer Centre, Arizona

4:45-5:15  
**Transforming oncology practice through implementation of comprehensive precision oncology testing**  
Prof. Gareth Williams, Medical Director, Oncologica

5:15-5:45  
**Personalising cancer diagnosis and treatment through computational modelling**  
Prof. Walter Kolch, Director, Systems Biology Ireland & Conway Institute, University College Dublin

**Meeting ends**
Saturday 30th September  
Mezzanine Suite, Herbert Park Hotel, Ballsbridge, Dublin 4

Registration from 8:30

9:00 – 9:15  Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

**NOVEL THERAPIES**  
Chair: Professor Joe Duffy

9:15-9:45  Targeting mutant p53 - from molecular biology to the clinic  
*Prof. Klas Wiman, Dept. of Oncology-Pathology, Karolinska Institute, Stockholm*

9:45-10:15  Patient selection for a PARPi: olaparib  
*Dr. Darren Hodgson, Senior Principal Scientist, iMed Oncology (AstraZeneca)*

10:15-10:45  A role for the p53 tumour suppressor in regulating DNA double strand break repair  
*Prof. Noel Lowndes, Centre for Chromosome Biology, National University of Ireland, Galway*

10:45-11:15  To combine or not to combine: development directions for ATR kinase inhibitors M6620 and M4344  
*Dr. Frank Zenke, Head of Cellular Pharmacology, Translational Innovation Platform Oncology, Merck*

11:15-11:30  Coffee break, Herbert Suite

**ANGIOGENESIS**  
Chair: Professor Robert Kerbel

11:30-12:00  Improving preclinical mouse models for experimental therapeutics: antiangiogenics & immunotherapy as examples  
*Prof. Robert Kerbel, Co-director, Toronto Angiogenesis Research Centre, Sunnybrook Health Science Centre, Toronto*

12:00-12:30  Angiogenesis Inhibitors in non-small cell lung cancer  
*Prof. Thomas Wehler, University of Saarland, Germany*

12:30-1:00  Antiangiogenic cancer therapy  
*Dr. Yihai Cao, Karolinska Institute, Stockholm*

1:00-2:00  Lunch, Herbert Suite
Balancing the host immunological and angiogenic responses to anti-cancer treatments can improve therapeutic outcome
Dr. Yuval Shaked, Russell Berrie Nanotechnology Institute Technion-Israel Institute of Technology

Vascular Promotion and improved cancer treatment – going against the grain
Dr. Kairbaan Hodivala-Dilke, Barts Cancer Institute, Queen Mary University of London

Harnessing the anti-angiogenic and anti-cancer stem cell properties of FKBPL; discovery to clinic
Prof. Tracey Robson, Head of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland

Coffee break, Herbert Suite

Targeting CDK4/6 in breast cancer; single agent, combination and overcoming resistance
Dr. Neil O'Brien, Assistant Professor, Department of Medicine, UCLA

CDK 4/6 inhibitors- clinical
Prof. Joyce O'Shaughnessy, Consultant Medical Oncologist, Baylor-Sammons Cancer Center and US Oncology, Dallas, Texas

Improving cancer therapy via CDK8/19 Mediator kinase
Prof. Igor Roninson, Director, Centre for Targeted Therapies, University of South Carolina

Meeting ends